Pulmonary fibrosis is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, leading to reduced lung compliance, impaired gas exchange, and progressive dyspnea.
The FDA has granted orphan drug designation to Nuformix PLC's tranilast lysate candidate for treating idiopathic pulmonary fibrosis. The designation provides regulatory incentives including potential market exclusivity in the US. Nuformix is a London-based developer focused on fibrosis and oncology treatments.
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07572383 |
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis |
RECRUITING | PHASE2 |
| NCT07571291 |
DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSIS |
ACTIVE_NOT_RECRUITING | |
| NCT07570888 |
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination. |
NOT_YET_RECRUITING | PHASE4 |
| NCT07542067 |
Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment |
COMPLETED | PHASE1/PHASE2 |
| NCT07464132 |
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases |
RECRUITING | PHASE1/PHASE2 |
| NCT07459205 |
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases |
NOT_YET_RECRUITING | |
| NCT07441408 |
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07396467 |
Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis |
ACTIVE_NOT_RECRUITING | |
| NCT07229716 |
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects |
RECRUITING | PHASE1 |
| NCT07061873 |
Physical Exercise Program for Adults With Diffuse Interstitial Lung Disease in a Pulmonary Rehabilitation Context |
ENROLLING_BY_INVITATION | NA |
